Atenolol: Differences in mode of action compared with other antihypertensives. An opportunity to identify features that influence outcome?

Current Pharmaceutical Design

Volumn 13, Issue 2, 2007, Pages 229-239

  Karagiannis, Asterios ^a   Mikhailidis, Dimitri P ^b   Kakafika, Anna I ^a,b   Tziomalos, Konstantinos ^a   Athyros, Vasilios G ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Atenolol; Beta blockers; Morbidity; Mortality; Primary hypertension; Vascular

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CELIPROLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; FELODIPINE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LACIDIPINE; LIPID; LOSARTAN; NEBIVOLOL; PERINDOPRIL; PLACEBO; PROPRANOLOL; RAMIPRIL; SOTALOL; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; UNINDEXED DRUG; URIC ACID; VERAPAMIL;

BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DIABETES MELLITUS; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM LESION; ERECTILE DYSFUNCTION; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE HYPERTROPHY; HEMODYNAMICS; HEMOSTASIS; HUMAN; HYPERTENSION; INSOMNIA; KIDNEY FUNCTION; META ANALYSIS; METABOLIC DISORDER; MONOTHERAPY; MOOD DISORDER; MORBIDITY; MORTALITY; NIGHTMARE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SIDE EFFECT; SYSTEMATIC REVIEW; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 33846122585     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207779313713     Document Type: Review

References (173)

1. Turnbull F. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 2003; 362: 1527-35.
2. WHO. World health report 2002; reducing risk, promoting healthy life. Geneva: World Health Organization. 2002.
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr. et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72.
4. Guidelines Committee. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertension 2003; 21: 1011-53.
5. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004; 328: 634-40.
6. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomized trial. Lancet 2001; 357: 1385-90.
7. Freemantle N, Cleland J, Young P, Mason J, Harisson J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. Br Med J 1999; 318: 1730-7.
8. Viscoli CM, Horwitz RJ, Singer BH. Beta-blockers after myocardial infarction: influence of first-year clinical course on long-term effectiveness. Ann Intern Med 1993; 118: 99-105.
9. Gheorgiade AV, Colucci WS, Swedberg K. Beta-blockers in chronic heart failure. Circulation 2003; 107: 1570-5.
10. Sin DD, McAlister FA. The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure. Am J Med 2002; 113: 650-6.
11. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.
12. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106: 2194-9.
13. Autore C, Spirito P, Spirito P. Approach to hypertrophic cardiomyopathy. Curr Treat Options Cardiovasc Med 2004; 6: 489-98.
14. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Kornajda M, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362: 7-13.
15. Carlberg B, Samuelson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004; 364: 1684-9.
16. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? Lancet 2005; 366: 1545-53.
17. Messerli FH, Beevers DO, Franklin SS, Pickering TG. Beta-blockers in hypertension-the emperor has no clothes: an open letter to present and prospective drafters of new guidelines for the treatment of hypertension. Am J Hypertens 2003; 16: 870-3.
18. Messerti FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? JAMA 1998; 279: 1903-7.
19. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med 11986; 293: 1145-51.
20. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992; 304: 405-12.
21. The Dutch TIA Trial Study Group. Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. Stroke 1993; 24: 543-8.
22. Eriksson S, Olofsson BO, Wester PO. Atenolol in the secondary prevention after stroke. Cerebrovasc Dis 1995; 5: 21-5.
23. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
24. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 1998; 317: 713-20.
25. Wilhelmsen L, Berglund G, Elmfeldt D, Fitzsimons T, Holzgreve H, Hosie J, et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987; 5: 561-72.
26. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atheroscierosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106: 2422-7.
27. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
28. Poulter NR, Wedel H, Dahlof B, Sever PS, Beevers DO, Caulfield M, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907-13.
29. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13.
30. Franklin SS, Jacobs MJ, Wong ND, L'Italien GJ, Lapuerta P. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 2001; 37: 869-74.
31. Kroeker EJ, Wood EH. Comparison of simultaneously recorded central and peripheral arterial pressure pulses during rest, exercise and tilted position in man. Circ Res 1955; 3: 623-32.
32. O'Rourke MF. From theory into practice: arterial haemodynamics in clinical hypertension. J Hypertens 2002; 20: 1901-15.
33. Kroeker EJ, Wood EH. Beat-to-beat alterations in relationship of simultaneously recorded central and peripheral arterial pressure pulses during Valsalva maneuver and prolonged expiration in man. J Appl Physiol 1956; 8: 483-494.
34. Chowienczyk PJ, Kelly RP, MacCallum H, Millasseau SC, Andersson TL, Gosling RG, et al. Photoplethysmographic assessment of pulse wave reflection: blunted response to endothelium-dependent beta2-adrenergic vasodilation in type II diabetes mellitus. J Am Coll Cardiol 1999; 34: 2007-14.
35. Wilkinson IB, Prasad K, Hall IR, Thomas A, MacCallum H, Webb DJ, et al. Increased central pulse pressure and augmentation index in subjects with hypercholesterolemia. J Am Coll Cardiol 2002; 39: 1005-11.
36. Wilkinson IB, MacCallum H, Flint L, Cockcroft JR, Newby DE, Webb DJ. The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol 2000; 525: 263-70.
37. Safar ME. Pulse pressure, arterial stiffness, and cardiovascular risk. Curr Opin Cardiol 2000; 15: 258-63.
38. Gardin JM, Arnold A, Gottdiener JS, Wong ND, Fried LP, Klopfenstein HS, et al. Left ventricular mass in the elderly. The Cardiovascular Health Study. Hypertension 1997; 29: 1095-103.
39. Franklin SS, Sutton-Tyrrell K, Belle SH, Weber MA, Kuller LH. The importance of pulsatile components of hypertension in predicting carotid stenosis in older adults. J Hypertens 1997; 10: 1143-50.
40. Ryan SM, Waack BJ, Weno BL, Heistad DD. Increases in pulse pressure impair acetylcholine-induced vascular relaxation. Am J Physiol 1995; 268: H359-H363.
41. Safar ME, Blacher J, Pannier B, Guerin AP, Marchais SJ, Guyonvarc'h PM, et al. Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002; 39: 735-8.
42. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. Differential Impact of Blood Pressure-Lowering Drugs on Central Aortic Pressure and Clinical Outcomes. Principal Results of the Conduit Artery Function Evaluation (CAFE) Study. Circulation 2006; 113: 1213-25.
43. Hirata K, Vlachopoulos C. Adji A, O'Rourke MF. Benefits from angiotensin-converting enzyme inhibitor "beyond blood pressure lowering": beyond blood pressure or beyond the brachial artery? J. Hypertens 2005; 23: 551-6.
44. Morgan T, Lauri J, Bertram D. Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004; 17: 118-23.
45. Dhakam Z, McEniery CM, - Yasmin, Cockcroft JR, Brown MJ, Wilkinson IB. Atenolol and Eprosartan: Differential Effects on Central Blood Pressure and Aortic Pulse Wave Velocity. Am J Hypertens 2006; 19: 214-9.
46. London GM, Asmar RG, O'Rourke MF, Safar ME. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 2004; 43: 92-9.
47. Fyhrquist F, Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, et al. Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. Hypertension 2005; 45: 580-5.
48. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.
49. Foley RN, Parfrey PS, Hamrtt JD, Kent GM, Murray DC, Barre PE. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 1995; 5: 2024-31.
50. Ghali JK, Liao Y, Simmons B, Castaner A, Cao G, Cooper RS. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med 1992; 117: 831-6.
51. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345-52.
52. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-6.
53. Koren MJ, Ulin RJ, Koren AT, Laragh JH, Devereux RB. Left ventricular mass change during treatment and outcome in patients with essential hypertension. Am J Hypertens 2002; 15: 1021-8.
54. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995; 13: 1091-5.
55. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97: 48-54.
56. Jula AM, Karanko HM. Effects on left ventricular hypertrophy of long-term nonpharmacological treatment with sodium restriction in mild-to-moderate essential hypertension. Circulation 1994; 89: 1023-31.
57. MacMahon SW, Wilcken DE, Macdonald GJ. The effect of weight reduction on left ventricular mass. A randomized controlled trial in young, overweight hypertensive patients. N Engl 3 Med 1986; 314: 334-9.
58. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115: 41-6.
59. Castellano M, Bohm M. The cardiac beta-adrenoceptor-mediated signaling pathway and its alterations in hypertensive heart disease. Hypertension 1997; 29: 715-22.
60. Olsen MH, Wachtell K, Tuxen C, Fossunt E, Bang LE, Hall C, et al. Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy. J Hypertens 2005; 23: 1083-90.
61. Agabiti-Rosei E, Trimarco B, Muiesan ML, Reid J, Salvetti A, Tang R, et al. Cardiac structural and functional changes during long-term antihypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2005; 23: 1091-8.
62. De Luca N, Mallion JM, O'Rourke MF, O'Brien E, Rahn KH, Trimarco B, et al. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study. Am J Hypertens 2004; 17: 660-7.
63. Nagano M, Higaki J, Mikami H, Nakamaru M, Higashimori K, Katahira K, et al. Converting enzyme inhibitors regressed cardiac hypertrophy and reduced tissue angiotensin II in spontaneously hypertensive rats. J Hypertens 1991; 9: 595-9.
64. Schmeider RE, Langenfeld MR, Friedrich A, Schobel HP, Gatzka CD, Weihprecht H. Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension. Circulation 1996; 94: 1304-9.
65. Schlaich MP, Schobel HP, Langenfeld MR, Hilgers K, Schmeider RE. Inadequate suppression of angiotensin II modulates left ventricular structure in humans. Clin Nephrol 1998; 49: 153-9.
66. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113: 356-64.
67. Tsang TS, Petty GW, Barnes ME, O'Fallon WM, Bailey KR, Wiebers DO, et al. The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. J Am Coll Cardiol 2003; 42: 93-100.
68. Vidaillet H, Granada JF, Chyou PH, Mitassen K, Ortiz M, Pulido JN, et al. A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med 2002; 113: 365-70.
69. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100: 376-80.
70. Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107: 2926-31.
71. Wachtell K, Lehto M, Gerdts E, Olsen MH, Homestam B, Dahlof B, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenotol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712-9.
72. Gerdts E, Oikarinen L, Palmieri V, Otterstad JE, Wachtell K, Boman K, et al. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Hypertension 2002; 39: 739-43.
73. Benjamin EJ, D'Agostino RB, Belanger AJ, Wolf PA, Levy D. Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation 1995; 92: 835-41.
74. Gottdiener JS, Reda DJ, Williams DW, Materson BJ, Cushman W, Anderson RJ. Effect of single-drug therapy on reduction of left atrial size in mild to moderate hypertension: comparison of six antihypertensive agents. Circulation 1998; 98: 140-8.
75. Devereux RB, Dahlof B, Gerdis E, Boman K, Nieminen M3, Papademetriou V, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004; 110: 1456-62.
76. Okin PM, Devereux RB, Jem S, Kjeldsen SE, Julius S, Nieminen MS, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation 2003; 108: 684-90.
77. Sanjuan R, Blasco M, Carbonell N, Jorda A, Nunez J, Martinez-Leon J et al. Preoperative use of sotalol versus atenolol for atrial fibrillation after cardiac surgery. Ann Thorac Surg 2004; 77: 838-43.
78. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003; 41: 2197-204.
79. Clausen-Sjobom N, Lins PE, Adamson U, Curstedt T, Hamberger B. Effects of metoprolol on the counter-regulation and recognition of prolonged hypoglycemia in insulin-dependent diabetics. Acta, Med Scand 1987; 222: 57-63.
80. Molnar GW, Read RC. Propranolol enhancement of hypoglycemic sweating. Clin Pharmacol Ther 1974; 15: 490-6.
81. Lee SP, Harris ND, Robinson RT, Davies C, Ireland R, Macdonald IA, et al. Effect of atenolol on QTc interval lengthening during hypoglycaemia in type 1 diabetes. Diabetologia 2005; 48: 1269-72.
82. Liberopoulos EN, Tsouli S, Mikhailidis DP, Elisaf MS. Preventing type 2 diabetes in high risk patients; an overview of lifestyle and pharmacological measures. Curr Drug Targets 2006; 7: 211-28.
83. Bengtsson C, Blohme G, Lapidus L, Lindquist O, Lundgren H, Nystrom E, et al. Do antihypertensive drugs precipitate diabetes? Br Med J 1984; 289: 1495-7.
84. Eberly LE, Cohen JD, Prineas R, Yang L. Impact of incident diabetes and incident nonfatal cardiovascular disease on 18-year mortality: the multiple risk factor intervention trial experience. Diabetes Care 2003; 26: 848-54.
85. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Br Med J 2003; 326: 1427.
86. Opie LH, Schall R. Old antihypertensives and new diabetes. J Hypertens 2004; 22: 1453-8.
87. Verdecchia P, Reboldi G, Argeli F, Borgioni C, Gattobigio R, Filippucci L, et al. Adverse prognostic signifcance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43: 963-9.
88. Jordan J, Engeli S, Boschmann M, Weidinger G, Luft FC, Sharma AM, et al. Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients. J Hypertens 2005; 23: 2313-8.
89. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.
90. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-6.
91. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRHOPE substudy. Lancet 2000; 355: 253-9.
92. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-31.
93. Pfeffer MA, Swedberg K, Granger CB. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-66.
94. Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif JC. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 2003; 107: 1291-6.
95. Wing LM, Reid CM, Ryan P, Beilin U, Brown MA, Jennings GL, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583-92.
96. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-71.
97. Lund-Johansen P. The role of drugs in countering adverse pathophysiological profiles: influence on hemodynamics. Am Heart J 1987; 114: 958-64.
98. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005; 23: 463-73.
99. Lind L, Pollare T, Berne C, Lithell H. Long-term metabolic effects of antiltypertensive drugs. Am Heart J 1994; 128: 1177-83.
100. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Pettiti M, Natali A, et al. Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance. Diabetologia. 2003; 46: 1211-9.
101. Expert Panel on Detection EaToHBCiA. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
102. Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991; 14: 203-9.
103. Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995; 122: 133-41.
104. Gonzalez M, I. Adrenoreceptors, endothelial function, and lipid profile: effects of atenolol, doxazosin, and carvedilol. Coron Artery Dis 1994; 5: 909-18.
105. Lehtonen A. Comparison of the metabolic effects of long-term treatment with pindolol or atenolol by hypertensive patients. Cardiovasc Drugs Ther 1988; 1: 549-51.
106. Sirtori CR, Johnson B, Vaccarino V, Montinari G, Cremoncini M, Gianfranceschi G, et al Lipid effects of celiprolol, a new cardioselective beta-blocker, versus propranolol. Clin Pharmacol Ther 1989; 45: 617-26.
107. Lijnen P. Biochemical mechanisms involved in the beta-blocker induced changes in serum lipoproteins. Am Heart J 1992; 124: 549-56.
108. Lithell H, Pollare T, Vessby B. Metabolic efiecEs of pindolol and propranolol in a double-blind cross-over study in hypertensive patients. Blood Press 1992; 1: 92-101.
109. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21: 1563-74.
110. Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991; 84: 613-7.
111. Jagroop IA, Kakafika IA, Mikhailidis DP. Platelets and vascular risk: an option for treatment. Curr Pharm Des 2006; In press.
112. Ganotakis ES, Papadakis JA, Vrentzos GE, Mikhailidis DP. The effects of antihypertensive therapy in haemostatic parameters. Curr Pharm Des 2003; 9: 2445-64.
113. Punda A, Polic S, Rumboldt Z, Bagatin J, Markovic V, Lukin A. Effects of atenolol and propranolol on platelet aggregation in moderate essential hypertension: randomized crossover trial. Croat Med J 2005; 46: 219-24.
114. Knight CJ, Panesar M, Wilson DJ, Chronos NA, Patel D, Fox K, et al. Different effects of calcium antagonists, nitrates, and beta-blockers on platelet function. Possible importance for the treatment of unstable angina. Circulation 1997; 95: 125-32.
115. Nosal R, Jancinova V, Petrikova M. On the relationship between the inhibition of thrombin stimulated aggregation and thromboxane formation in isolated platelets treated with beta-adrenoceptor blocking drugs. Thromb Res 1992; 68: 333-44.
116. Papadakis JA, Ganotakis ES, Jagroop IA, Mikhailidis DP, Winder AF. Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia. Am J Hypertens 1999; 12: 673-81.
117. Papadakis JA, Mikhailidis DP, Vrentzos GE, Kalikaki A, Kazakou I, Ganotakis ES. Effect of antihypertensive treatment on plasma fibrinogen and serum HDL levels in patients with essential hypertension. Clin Appl Thromb Hemost 2005; 11: 139-46.
118. Haenni A, Lithell H. Urapidil treatment decreases plasma fibrinogen concentration in essential hypertension. Metabolism 1996; 45: 1221-9.
119. Makris TK, Stavroulakis GA, Krespi PG, Hatzizacharias AN, Triposkiadis FK, Tsoukala CG, et al. Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. Am J Hypertens 2000; 13: 783-8.
120. Rizos E, Bairaktari E, Kostoula A, Hasiotis G, Achimastos A, Ganotakis E, et al. The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. J Cardiovasc Pharmacol Ther 2003; 8: 127-34.
121. Jonsson G, Fossum E, Kjeldsen SE, Hoieggen A, Os I, Eide I, et al. Lower plasma noradrenaline and blood viscosity on carvedilol vs atenolol in men with recent myocardial infarction. Blood Press 2002; 11: 377-84.
122. Segura J, Ruilope LM. Minor abnormalities of renal function: a situation requiring integrated management of cardiovascular risk. Fund Clin Pharmacol 2005; 19: 429-37.
123. Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens 2004; 22: 1805-11.
124. PROCOPA Study Group. Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomized double-blind trial. J Hypertens 2002; 20: 729-37.
125. van Essen GG, Apperloo AJ, Rensma PL, Stegeman CA, Sluiter WJ, de Zeeuw D, et al. Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline? Kidney Int Suppl 1997; 63: S58-S62.
126. Hausberg M, Barenbrock M, Hohage H, Muller S, Heidenreich S, Rahn KH. ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients. Hypertension 1999; 33: 862-8.
127. Garg J, Bakris GL. Treatment of hypertension in patients with renal disease. Cardiovasc Drugs 2002; 16: 503-10.
128. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, et al. The effect of statins versus untreated dysiipidaemia on renai function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004; 57: 728-34.
129. Athyros VG, Elisaf MS, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, et al. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart disease Evaluation (GREACE) study. Am J Kidney Dis 2004; 43: 589-99.
130. Daskalopoulou S, Athyros VG, Elisaf M, Mikhailidis DP. Uric acid levels and vascular disease. Curr Med Res Opin 2004; 20: 951-4.
131. Hoieggen A, Alderman MH, Kjeldsen SE, Julius S, Devereux RB, De Faire U, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041-9.
132. Mosenkis A, Townsend RR. Antihypertensive medications and weight gain. J Clin Hypertens 2004; 6: 90.
133. Lindholm LH, Ibsen H, Borch-Johnsen K. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002; 20: 1879-86.
134. Daskalopoulou SS, Tzovaras V, Mikhailidis DP, Elisaf M. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr Pharm Des 2005; 11: 4161-75.
135. London GM, Marchais SJ, Guerin AP, Metivier F, Adda H, Pannier B. Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients. Kidney Int Suppl 2003; 84: S88-S93.
136. Abramson JL, Weintraub WS, Vaccarino V. Association between pulse pressure and C-reactive protein among apparently healthy US adults. Hypertension 2002; 39: 197-202.
137. Amar J, Ruidavets JB, Sollier CB, Bongard V, Boccalon H, Chamontin B, et al. Relationship between C-reactive protein and pulse pressure is not mediated by atherosclerosis or aortic stiffness. J Hypertens 2004; 22: 349-55.
138. Amar J, Ruidavets JB, Peyrieux JC, Mallion JM, Ferrieres J, Safar ME, et al. C-reactive protein elevation predicts pulse pressure reduction in hypertensive subjects. Hypertension 2005; 46: 151-5.
139. Ray KK, Cannon CP, Cairns R, Morrow DA, Rifai N, Kirtane AJ, et al. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TTMI 22 trial. J Am Coll Cardiol 2005; 46: 1417-24.
140. Ablad B, Bjuro T, Bjorkman JA, Edstrom T, Olsson G. Role of central nervous beta-adrenoreceptors in the prevention of ventricular fibrillation through augmentation of cardiac vagal tone. J Am Coll Cardiol 1991; 17 (suppl): 165.
141. Parker GW, Michael LH, Hartley CJ, Skinner JE, Entman ML. Central beta-adrenergic mechanisms may modulate ischemic ventricular fibrillation in pigs. Circ Res 1990; 66: 259-70.
142. Schiffirin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101: 1653-9.
143. Schiffirin EL, Deng LY, Larochelle P. Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin I-converting enzyme inhibitor. Comparison with effects of a beta-blocker. Am J Hypertens 1995; 8: 229-36.
144. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A. Antihypertensive drugs and reversing of endothelial dysfunction in hypertension. Curr Hypertens Rep 2000; 2: 64-70.
145. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. Drugs 2002; 65: 265-84.
146. Cockcroft JR. Exploring vascular benefits of endothelium-derived nitric oxide. Am J Hypertens 2005; 18: 177S-83S.
147. Lekakis JP, Protogerou A, Papamichael C, Vamvakou G, Iconomidis I, Fici F, et al. Effect of nebivolol and atenolol on brachial artery flow-mediated vasodilation in patients with coronary artery disease. Cardiovasc Drugs 2005; 19: 277-81.
148. Ghiadoni L, Magagna A, Versari D, Kardasz I, Huang Y, Taddei S, et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003; 41: 1281-6.
149. Schiffrin EL, Park JB, Pu Q. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function. J Hypertens 2002; 20: 71-8.
150. Brunner H, Cockroft JR, Deanfieid J, Donald A, Ferannini E, Halcox J, et al. Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23: 233-46.
151. Olsen MH, Wachtell K, Neland K, Bella JN, Rokkedal J, Dige-Petersen H, et al. Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy. Blood Press 2005; 14: 177-83.
152. Paliotti R, Ciulla MM, Hennig M, Tang R, Bond MG, Mancia G, et al. Carotid wall composition in hypertensive patients after 4-year treatment with lacidipine or atenolol: an echoreflectivity study. J Hypertens 2005; 23: 1203-9.
153. Yetman AT, Bornemeier RA, McCrindle BW. Usefulness of enalapril versus propanolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. Am J Cardiol 2005; 95: 1125-7.
154. Meijboom LJ, Westerhof BE, Nollen GJ, Spaan JA, de Mol BA, Jacobs MJ, et al. Beta-blocking therapy in patients with the Marfan syndrome and entire aortic replacement. Eur J Cardiothorac Surg 2004; 26: 901-6.
155. Solomon SA, Ramsay LE, Yeo WW, Parnell L, Morris-Jones W. beta blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination. BMJ 1991; 303: 1100-4.
156. Kotamaki M, Manninen V, Laustiola KE. Enalapril versus atenolol in the treatment of hypertensive smokers. Eur J Clin Pharmacol 1993; 44: 13-7.
157. Vyssoulis GP, Karpanou EA, Pitsavos CE, Toutouza MA, Paleologos AA, Toutouzas PK. Dyslipidemic effects of cigarette smoking on beta-blocker-induced serum lipid changes in systemic hypertension. Am L Cardiol 1991; 67: 987-92.
158. Reims HM, Oparil S, Kjeldsen SE, Devereux RB, Julius S, Brady WE, et al. Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study. Blood Press 2004; 13: 376-84.
159. Milionis HJ, Rizos E, Mikhailidis DP. Smoking diminishes the beneficial effect of statins: observations from the landmark trials. Angiology 2001; 52: 575-87.
160. Fodor JG, Chockalingam A, Drover A, Fifield F, Pauls CJ. A comparison of the side effects of atenolol and propranolol in the treatment of patients with hypertension. J Clin Pharmacol 1987; 27: 892-901.
161. Mikhailidis DP, Khan MA, Milionis HJ, Morgan RJ. The treatment of hypertension in patients with erectile dysfunction. Curr Med Res Opin 2000; 16: S31-S36.
162. Fogari R, Preti P, Derosa G, Marasi G, Zoppi A, Rinaldi A, et al. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol 2002; 58: 177-80.
163. Toblli J, Stella I, Nestor Mazza O, Ferder L, Inserra F. Protection of cavernous tissue in male spontaneously hypertensive rats. Beyond blood pressure control. Am J Hypenens 2004; 17: 516-22.
164. Silvestri A, Galetta P, Cerquetani E, Marazzi G, Patrizi R, Fini M, et al. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J 2003; 24: 1928-32.
165. Hjalmarson A. Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter? Basic Res Cardiol 2000; 95 Suppl 1: 141-5.
166. Tuininga YS, Crijns HJ, Brouwer J, van den Berg MP, Man in't Veld AJ, Mulder G, et al. Evaluation of importance of central effects of atenolol and metoprolol measuredby heart rate variability during mental performance tasks, physical execise,and daily life in stable postinfarct patients. Circulation 1995; 92: 3415-23.
167. Ellison KE, Gandhi G. Optimising the use of beta-adrenoceptor antagonists in coronary artery disease. Drugs 2005; 65: 787-97.
168. Gottlieb SS, McCarter RJ. Comparative effects of three beta blockers (atenolol, metoprolol, and propranolol) on survival after acute myocardial infarction. Am J Cardiol 2001; 87: 823-6.
169. Redelmeier D, Scales D, Kopp A. Beta blockers for elective surgery in elderly patients: population based, retrospective cohort study. BMJ 2005; 331: 932.
170. Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 1989; 298: 1152-7.
171. Blacher J, Protogerou AD, Safar ME. Large artery stiffness and antihypertensive agents. Curr Pharm Des 2005; 11(25): 3317-26.
172. Jaumdally JR, Lip GY, Varma C. Traditional risk factors for coronary atherosclerosis in Indo Asians: the need for a reappraisal. Curr Pharm Des 2006; 12(13): 1611-21.
173. Sagnella GA, Swift PA. The renal epithelial sodium channel: genetic heterogeneity and implications for the treatment of high blood pressure. Curr Pharm Des 2006; 12(18): 2221-34.